Some Generics May Get To Skip Fed Study Requirement If US FDA Research Pans Out
Executive Summary
Office of Generic Drugs official says the FDA may be able to harmonize its requirements with regulators who do not have a blanket mandate.
You may also be interested in...
CMS Needs Regulatory Science, Chief Scientist To Coordinate With US FDA, Former Official Says
Sean Tunis embraces a bigger decision-making role for CMS in product access, while FDA Commissioner nominee Robert Califf also calls for smoother FDA-CMS hand-offs, and CBER Director Peter Marks wants a quicker FDA-CDC approval and deployment process.
US FDA Crowdsourcing Pediatric Regulatory Science Research Ideas
With more than 1,600 pediatric and related clinical trials in house, the agency wants ideas for how they can be analyzed to advance pediatric drug development.
Generic Industry Market Forces May Impact GDUFA III Talks
AAM's Chip Davis said a user fee cut is not in order, but industry consolidation and product launch problems may mean it cannot accept another large increase.